Superworth4D Molecular Therapeutics EPS FDMT
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$2.76
- Latest quarter, Q2 FY26
- −$1.04
- Fiscal year 2025
- −$2.55
4D Molecular Therapeutics' earnings per share was −$2.76 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.04.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$2.55 | n/a |
| FY2024 | −$2.97 | n/a |
| FY2023 | −$2.64 | n/a |
| FY2022 | −$3.32 | n/a |
| FY2021 | −$2.53 | n/a |
| FY2020 | −$9.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.04 | n/a | −$2.76 | |
| Q1 FY26 | −$1.01 | n/a | −$2.70 | |
| Q4 FY25 | $0.30 | n/a | −$2.55 | |
| Q3 FY25 | −$1.01 | n/a | −$3.74 | |
| Q2 FY25 | −$0.98 | n/a | −$3.52 | |
| Q1 FY25 | −$0.86 | n/a | −$3.17 | |
| Q4 FY24 | −$0.89 | n/a | −$2.97 | |
| Q3 FY24 | −$0.79 | n/a | −$2.83 | |
| Q2 FY24 | −$0.63 | n/a | −$2.28 | |
| Q1 FY24 | −$0.66 | n/a | −$2.42 | |
| Q4 FY23 | −$0.75 | n/a | −$2.64 | |
| Q3 FY23 | −$0.24 | n/a | −$2.73 |
Against its peers
Companies in Biotechnology nearest 4D Molecular Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| FDMT4D Molecular Therapeutics | −$2.76 | |
| MGTXMeiraGTx | $0.71 | |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $0.58 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on 4D Molecular Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.